Breast Cancer Risk Calculator (Gail Model)

The Gail Model (also known as the Breast Cancer Risk Assessment Tool or BCRAT) is the most widely used tool for estimating a woman's risk of developing invasive breast cancer over the next 5 years and over her lifetime. Originally developed by Dr. Mitchell Gail and colleagues at the National Cancer Institute in 1989, this model has been extensively validated and updated over more than three decades.

Breast cancer is the most common cancer in women worldwide, affecting approximately 1 in 8 women over their lifetime. In the United States alone, over 300,000 new cases of invasive breast cancer are diagnosed annually. Risk stratification is essential for making informed decisions about screening intensity, chemoprevention, and genetic counseling referrals.

The Gail Model incorporates six key risk factors: current age, age at menarche, age at first live birth, number of first-degree relatives with breast cancer, number of previous breast biopsies, and the presence of atypical hyperplasia on any biopsy. Each factor has been shown to independently contribute to breast cancer risk in large epidemiological studies.

A critical threshold in the Gail Model is a 5-year risk of 1.67% or higher. This threshold, established in the landmark NSABP P-1 (Breast Cancer Prevention Trial), identifies women who may benefit from chemoprevention with tamoxifen, raloxifene, or aromatase inhibitors. The FDA approved tamoxifen for breast cancer risk reduction based on this threshold.

The model estimates provided are population-level approximations. The true Gail Model calculation uses complex age-specific hazard rates and competing mortality rates that require the full NCI algorithm. This calculator provides a relative risk score and approximate 5-year risk estimate for screening purposes. For precise individual risk estimates, the NCI's official Breast Cancer Risk Assessment Tool should be used.

Important limitations of the Gail Model include its inability to account for BRCA1/2 mutations, family history beyond first-degree relatives, breast density, and other genetic risk factors. Women with known hereditary breast cancer syndromes should be assessed with models like BRCAPRO or Tyrer-Cuzick (IBIS) that incorporate more detailed genetic and family history information.